Quantification of beta-catenin signaling components in colon cancer cell lines, tissue sections, and microdissected tumor cells using reaction monitoring mass spectrometry.
about
Applications of targeted proteomics in systems biology and translational medicineEmerging proteomic technologies for elucidating context-dependent cellular signaling events: A big challenge of tiny proportionsProteomics of ovarian cancer: functional insights and clinical applicationsEvaluating melanoma drug response and therapeutic escape with quantitative proteomicsPTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expressionMonitoring a nuclear factor-κB signature of drug resistance in multiple myeloma.Evaluating kinase ATP uptake and tyrosine phosphorylation using multiplexed quantification of chemically labeled and post-translationally modified peptides.Quantitative Profiling of Protein Tyrosine Kinases in Human Cancer Cell Lines by Multiplexed Parallel Reaction Monitoring AssaysAdvancing the sensitivity of selected reaction monitoring-based targeted quantitative proteomics.Evaluation of protein quantification using standard peptides containing single conservative amino acid replacementsQuantitative mass spectrometry analysis of PD-L1 protein expression, N-glycosylation and expression stoichiometry with PD-1 and PD-L2 in human melanoma.A database of reaction monitoring mass spectrometry assays for elucidating therapeutic response in cancerQuantitative multiple reaction monitoring of peptide abundance introduced via a capillary zone electrophoresis-electrospray interfaceReview of software tools for design and analysis of large scale MRM proteomic datasets.Connecting genomic alterations to cancer biology with proteomics: the NCI Clinical Proteomic Tumor Analysis ConsortiumA Timely Shift from Shotgun to Targeted Proteomics and How It Can Be Groundbreaking for Cancer Research.Quantitative mass spectrometry for colorectal cancer proteomics.Targeted proteomics of solid cancers: from quantification of known biomarkers towards reading the digital proteome maps.Quantitative proteomics of breast tumors: Tissue quality assessment to clinical biomarkers.Oncogenic KRAS and BRAF Drive Metabolic Reprogramming in Colorectal Cancer.Comparison of commercial nanoliquid chromatography columns for fast, targeted mass spectrometry-based proteomics.Comparative LC-MS/MS analysis of optimal cutting temperature (OCT) compound removal for the study of mammalian proteomes.Modeling Wnt/β-Catenin Target Gene Expression in APC and Wnt Gradients Under Wild Type and Mutant ConditionsInhibition of PI3K/Akt/mTOR signaling in PI3KR2-overexpressing colon cancer stem cells reduces tumor growth due to apoptosis.Quantification of Breast Cancer Protein Biomarkers at Different Expression Levels in Human Tumors.Comparison of Quantitative Mass Spectrometry Platforms for Monitoring Kinase ATP Probe Uptake in Lung Cancer.Application of targeted mass spectrometry in bottom-up proteomics for systems biology research.Mathematical modelling suggests a differential impact of β-transducin repeat-containing protein paralogues on Wnt/β-catenin signalling dynamics.Monitoring protein expression in whole-cell extracts by targeted label- and standard-free LC-MS/MS.Proteomics meets the scientific method.
P2860
Q26852271-7561604E-78F4-414D-A819-EFD47140ACC2Q28081956-19563C1D-CED3-4154-9F4E-ECA28E704D58Q28082632-3A5F3196-EDF8-4F54-997A-DB8C1805302AQ33850665-B07844C0-F021-420E-94B5-2DA4ACD40578Q34761941-E4E0EBDC-1B5C-4AB7-B906-E544A8BA2490Q35579598-E9B4264D-E3A4-43D3-8CA4-F2875304A9DAQ35579916-E5454171-8F84-4487-8692-50F23BBF93E4Q35859573-05E0C19C-7B4E-4CB6-A1B0-E55F05336A5BQ36031629-6F3403BB-2CA5-4624-B3C0-2C64D7B9C49BQ36301398-BBC02D70-AFC9-4C43-BBCB-1CD5329200A4Q36382143-75F4791C-B9BF-440C-A505-B22785CA261BQ36490656-5E7D8CF7-D92D-433E-9136-BB3316547B14Q36907471-C585F632-DC2F-457A-AB7B-02F9BDD3B126Q37177456-94180BCD-F491-4467-B0DB-2ABFE3EBB7FBQ37238264-D15927ED-74FC-4A5D-955D-6C95C4AB6D96Q37651691-8DFBB34D-3224-439B-A3CB-0D4247976A81Q38048726-F1AFB944-56C8-4F1C-873A-3D07B8146912Q38604366-8F148F25-5F2D-4712-8704-F869DC7D66D8Q38719192-35939911-C012-4A44-9E70-D8C714C91EFDQ38762520-65F42E3D-27FB-4EB2-B651-58F8B52D69BBQ38776809-F19027B2-17C9-4D33-B70D-746868536BACQ39093951-90930997-99D3-4E28-9FEE-F9112B52EA7AQ41545327-B9565989-6C3D-476D-A388-203C5F43DDE1Q41612097-52B4F4A9-8216-457E-9CFB-7E73C276702FQ47291460-885F551C-BA51-4907-AC45-DE94FDD3A6E4Q47374639-CBA2A13A-5CFD-4A8C-B8A4-DCD1EB7DD435Q49922966-9838F3F2-F1CD-49BC-AB13-A28D2D351EB7Q50974518-C2904EB3-B3D3-4A51-9533-B1D226BC7DA0Q52894941-BCEFD78A-F994-45BE-9B81-A0135EFF32DBQ55056925-4B4CE90B-C552-4F04-A21E-2FB61400190C
P2860
Quantification of beta-catenin signaling components in colon cancer cell lines, tissue sections, and microdissected tumor cells using reaction monitoring mass spectrometry.
description
2010 nî lūn-bûn
@nan
2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Quantification of beta-catenin ...... monitoring mass spectrometry.
@ast
Quantification of beta-catenin ...... monitoring mass spectrometry.
@en
type
label
Quantification of beta-catenin ...... monitoring mass spectrometry.
@ast
Quantification of beta-catenin ...... monitoring mass spectrometry.
@en
prefLabel
Quantification of beta-catenin ...... monitoring mass spectrometry.
@ast
Quantification of beta-catenin ...... monitoring mass spectrometry.
@en
P2093
P2860
P356
P1476
Quantification of beta-catenin ...... monitoring mass spectrometry.
@en
P2093
Aejaz Nasir
David Shibata
Elizabeth Remily-Wood
John M Koomen
Marilyn M Bui
Mark Lloyd
Mike Gruidl
Richard Z Liu
Steven Eschrich
Timothy Yeatman
P2860
P304
P356
10.1021/PR1005197
P577
2010-08-01T00:00:00Z